Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2018

21.12.2017 | editorial

My burning issues in TKI therapy and treatment-free remission in CML

verfasst von: MD Dominik Wolf

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

We all agree that treatment-free remission (TFR) is a common goal we aim for in cancer treatment. Even though many malignant diseases require long-term/maintenance therapies (i. e., IMiD maintenance in myeloma, antihormonal therapy in hormone-receptor-positive breast cancer or JAK inhibitors in myelofibrosis patients ineligible for allo-SCT), this often induces clinically relevant side effects lowering quality of life (QoL) and frequently also requires more intense clinical monitoring. For years, we also communicated the necessity of continuous life-long tyrosine kinase inhibitor (TKI) therapy to our patients with chronic myeloid leukemia (CML), until seminal work by F.X. Mahon and his French colleagues demonstrated that even though in some patients low-level disease burden fluctuates upon TKI withdrawal, approximately half of those patients can be successfully discontinued from targeted therapy for the long-term [ 1]. However, only a small proportion of optimal responders can continuously stop therapy (overall a maximum of 25% of chronic phase CML [CP-CML] patients treated up-front with 2nd generation TKIs are in long-term TFR). However, for me the following questions remain to be answered. …
Literatur
1.
Zurück zum Zitat Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298–305. CrossRefPubMed Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298–305. CrossRefPubMed
3.
Zurück zum Zitat Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5‑year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–54. CrossRefPubMedPubMedCentral Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5‑year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–54. CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3‑year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123:494–500. CrossRefPubMedPubMedCentral Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3‑year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123:494–500. CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525–31. CrossRefPubMedPubMedCentral Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525–31. CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733–7. CrossRefPubMed Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733–7. CrossRefPubMed
7.
Zurück zum Zitat Sopper S, Mustjoki S, White D, et al. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2017;35:175–84. CrossRefPubMed Sopper S, Mustjoki S, White D, et al. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2017;35:175–84. CrossRefPubMed
8.
Zurück zum Zitat Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48–56. CrossRefPubMed Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48–56. CrossRefPubMed
9.
Zurück zum Zitat Mahon FX, Richter J, Guilhot J, et al. Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski Trial. Blood. 2016;128(22):787. Mahon FX, Richter J, Guilhot J, et al. Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski Trial. Blood. 2016;128(22):787.
10.
Zurück zum Zitat Ilander M, Olsson-Strömberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31:1108–16. CrossRefPubMed Ilander M, Olsson-Strömberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31:1108–16. CrossRefPubMed
11.
Zurück zum Zitat Rea D, Henry G, Khaznadar Z, et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. 2017;102:1368–77. CrossRefPubMed Rea D, Henry G, Khaznadar Z, et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. 2017;102:1368–77. CrossRefPubMed
12.
Zurück zum Zitat Schütz C, Inselmann S, Sausslele S, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2017;31:829–36. CrossRefPubMed Schütz C, Inselmann S, Sausslele S, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2017;31:829–36. CrossRefPubMed
13.
Zurück zum Zitat Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126:1762–9. CrossRefPubMedPubMedCentral Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126:1762–9. CrossRefPubMedPubMedCentral
Metadaten
Titel
My burning issues in TKI therapy and treatment-free remission in CML
verfasst von
MD Dominik Wolf
Publikationsdatum
21.12.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0377-6

Weitere Artikel der Ausgabe 1/2018

memo - Magazine of European Medical Oncology 1/2018 Zur Ausgabe